<DOC>
	<DOCNO>NCT01177683</DOCNO>
	<brief_summary>This open label phase I/II trial determine safety biologic activity bendamustine , bortezomib pegylated liposomal doxorubicin combination .</brief_summary>
	<brief_title>Bendamustine Combination With Bortezomib Pegylated Liposomal Doxorubicin Multiple Myeloma</brief_title>
	<detailed_description>Phase I component Bortezomib 1.3 mg/m2 IV bolus , Days 1 , 4 , 8 , 11 Doxorubicin 30 mg/m2 IV 1 hour , Day 4 Bendamustine escalate cohort IV 1 hour , Days 1 4 1 Cycle = 28 day Phase II component Bortezomib 1.3 mg/m2 IV bolus , Days 1 , 4 , 8 , 11 Doxorubicin 30 mg/m2 IV 1 hour , Day 4 Bendamustine MTD IV 1 hour , Days 1 4 Filgrastim ( define MTD ) 5 µg/kg/day SC , Starting day 6 neutrophil recovery ANC &gt; 1000 1 Cycle = 28 day ; Patients continue treatment total 8 cycle . ECOG Performance Status : 0-2 Hematopoietic : - Absolute neutrophil count ( ANC ) ≥ 1.2 x K/mm3 - Platelets ≥ 75 x K/mm3 Hepatic : - Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) - AST ≤ 2.5 x ULN - ALT ≤ 2.5 x ULN Renal : - Serum creatinine &lt; 3.0 mg/dL Cardiovascular : - LVEF &gt; 45 % correct MUGA scan echocardiogram . - No unstable angina pectoris recent myocardial infarction ( within 6 month )</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>A histologically establish diagnosis multiple myeloma evidence relapse refractory disease . Must detectable serum urine MProtein protein electrophoresis least 500 mg/dL ( serum ) 1 gm/24 hour ( urine ) , respectively , serum free light chain level &gt; 100 mg/l involve free light chain . Must receive least one ( 1 ) prior line systemic treatment include either lenalidomide thalidomide . Must willing provide correlative blood sample . Must receive excessive cumulative dose anthracycline No ≥ grade 2 peripheral neuropathy . No cytotoxic chemotherapy within 30 day prior registration protocol therapy . No autologous stem cell transplant within 6 month prior registration protocol therapy No prior radiation therapy &gt; 25 % bone marrow form bone ( i.e. , pelvis ) within 30 day prior registration protocol therapy . See Study Procedures Manual calculate percent prior radiation . No current corticosteroid therapy dose great 10 mg daily prednisone ( equivalent ) give management comorbid condition . No known central nervous system involvement myeloma . No poorly control intercurrent illness include , limited , ongoing active infection , poorly control diabetes , symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social climate opinion investigator would limit compliance study requirement . No patient know positive HIV , active Hepatitis A , B , C. No major surgery within 30 day prior registration protocol therapy . Placement venous access device within 30 day prior registration protocol therapy allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>